Literature DB >> 16234515

Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Andrea Eisen1, Jan Lubinski, Jan Klijn, Pal Moller, Henry T Lynch, Kenneth Offit, Barbara Weber, Tim Rebbeck, Susan L Neuhausen, Parviz Ghadirian, William D Foulkes, Ruth Gershoni-Baruch, Eitan Friedman, Gadi Rennert, Teresa Wagner, Claudine Isaacs, Charmaine Kim-Sing, Peter Ainsworth, Ping Sun, Steven A Narod.   

Abstract

PURPOSE: The purpose of this study was to estimate the extent of protection offered against breast cancer by prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations and to determine to what extent risk reduction varies with age at oophorectomy, age at diagnosis, and time elapsed since surgery. PATIENTS AND METHODS: We analyzed 1,439 patients with breast cancer and 1,866 matched controls derived from a registry of BRCA1 and BRCA2 carriers. We estimated odds ratios (ORs) of breast cancer for having had a bilateral oophorectomy, using conditional logistic regression, matched for parity and for oral contraceptive use.
RESULTS: A previous history of oophorectomy was associated with a significant reduction in breast cancer risk of 56% for BRCA1 carriers (OR = 0.44; 95% CI, 0.29 to 0.66) and of 46% for BRCA2 carriers (OR = 0.57; 95% CI, 0.28 to 1.15). The risk reduction was greater if the oophorectomy was performed before age 40 (OR = 0.36; 95% CI, 0.20 to 0.64 for BRCA1 carriers) than after age 40 (OR = 0.53; 95% CI, 0.30 to 0.91). The protective effect was evident for 15 years post-oophorectomy (OR = 0.39; 95% CI, 0.26 to 0.57).
CONCLUSION: Oophorectomy is an effective means of reducing the risk of breast cancer in carriers of BRCA1 mutations. The data suggest oophorectomy is protective in BRCA2 carriers as well, but needs to be confirmed in other studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16234515     DOI: 10.1200/JCO.2004.00.7138

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  117 in total

1.  No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Authors:  Larissa A Korde; Christine M Mueller; Jennifer T Loud; Jeffery P Struewing; Kathy Nichols; Mark H Greene; Phuong L Mai
Journal:  Breast Cancer Res Treat       Date:  2010-05-11       Impact factor: 4.872

Review 2.  Genetics for the general internist.

Authors:  Christina M Laukaitis
Journal:  Am J Med       Date:  2011-11-11       Impact factor: 4.965

3.  BRCA1 is required for postreplication repair after UV-induced DNA damage.

Authors:  Shailja Pathania; Jenna Nguyen; Sarah J Hill; Ralph Scully; Guillaume O Adelmant; Jarrod A Marto; Jean Feunteun; David M Livingston
Journal:  Mol Cell       Date:  2011-09-29       Impact factor: 17.970

Review 4.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

5.  The risk of breast cancer in women with a BRCA1 mutation from North America and Poland.

Authors:  Jan Lubinski; Tomasz Huzarski; Tomasz Byrski; Henry T Lynch; Cezary Cybulski; Parviz Ghadirian; Malgorzata Stawicka; William D Foulkes; Ewa Kilar; Charmaine Kim-Sing; Susan L Neuhausen; Susan Armel; Dawna Gilchrist; Kevin Sweet; Jacek Gronwald; Andrea Eisen; Bohdan Gorski; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2011-09-22       Impact factor: 7.396

6.  Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.

Authors:  Soley Bayraktar; Angelica M Gutierrez-Barrera; Diane Liu; Tunc Tasbas; Ugur Akar; Jennifer K Litton; E Lin; Constance T Albarracin; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun
Journal:  Breast Cancer Res Treat       Date:  2011-08-10       Impact factor: 4.872

7.  Salpingectomy to prevent ovarian cancer: A Countercurrents Series.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

Review 8.  Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.

Authors:  Tuya Pal; Susan T Vadaparampil
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

9.  Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.

Authors:  Laura L Holman; Sue Friedman; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

10.  Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.

Authors:  P Shah; M Rosen; J Stopfer; J Siegfried; R Kaltman; B Mason; K Armstrong; K L Nathanson; M Schnall; S M Domchek
Journal:  Breast Cancer Res Treat       Date:  2009-07-17       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.